Abstract
Type 2 diabetes (T2D) is considered an epidemic in the United States and presents a major economic strain on patients and the health care system. Patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2i) for T2D management are predisposed to genitourinary infections and Fournier gangrene. This article provides details on an overview of SGLT2i, including their use in the treatment of T2D, associated genitourinary infections and the effect of T2D on lower urinary tract (LUT) dysfunction. Nonpharmacologic and pharmacologic management strategies are also included to manage genitourinary side effects of SGLT2i and optimize bladder function and possibly minimize LUT dysfunction.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
